{"id":"https://openalex.org/W4308384128","doi":"https://doi.org/10.1136/jitc-2022-sitc2022.0732","title":"732 First-in-human trial to evaluate safety, PK/PD and initial clinical activity of NM21\u20131480, an affinity-balanced PD-L1x4\u20131BBxHSA trispecific antibody: results of phase 1 dose escalation","display_name":"732 First-in-human trial to evaluate safety, PK/PD and initial clinical activity of NM21\u20131480, an affinity-balanced PD-L1x4\u20131BBxHSA trispecific antibody: results of phase 1 dose escalation","publication_year":2022,"publication_date":"2022-11-01","ids":{"openalex":"https://openalex.org/W4308384128","doi":"https://doi.org/10.1136/jitc-2022-sitc2022.0732"},"language":"en","primary_location":{"id":"doi:10.1136/jitc-2022-sitc2022.0732","doi":"https://doi.org/10.1136/jitc-2022-sitc2022.0732","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2022-sitc2022.0732","pdf_url":"https://jitc.bmj.com/content/jitc/10/Suppl_2/A764.full.pdf","source":{"id":"https://openalex.org/S4363604233","display_name":"Regular and Young Investigator Award Abstracts","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular and Young Investigator Award Abstracts","raw_type":"proceedings-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://jitc.bmj.com/content/jitc/10/Suppl_2/A764.full.pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5063337705","display_name":"Jason J. Luke","orcid":"https://orcid.org/0000-0002-1182-4908","observed_orcids":["https://orcid.org/0000-0002-1182-4908"]},"institutions":[{"id":"https://openalex.org/I170201317","display_name":"University of Pittsburgh","ror":"https://ror.org/01an3r305","country_code":"US","type":"education","lineage":["https://openalex.org/I170201317"]},{"id":"https://openalex.org/I4210128526","display_name":"UPMC Hillman Cancer Center","ror":"https://ror.org/03bw34a45","country_code":"US","type":"facility","lineage":["https://openalex.org/I170201317","https://openalex.org/I4210128526"]},{"id":"https://openalex.org/I4210134769","display_name":"University of Pittsburgh Medical Center","ror":"https://ror.org/04ehecz88","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210098814","https://openalex.org/I4210134769"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jason Luke","raw_affiliation_strings":["Cancer Immunotherapeutics Center, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer Immunotherapeutics Center, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA","institution_ids":["https://openalex.org/I170201317","https://openalex.org/I4210128526","https://openalex.org/I4210134769"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049294543","display_name":"Melissa Lynne Johnson","orcid":"https://orcid.org/0000-0001-9874-1314","observed_orcids":["https://orcid.org/0000-0001-9874-1314"]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Melissa Johnson","raw_affiliation_strings":["Department of Medicine, Sarah Cannon Research Institute, Nashville, USA, Nashville, TN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Sarah Cannon Research Institute, Nashville, USA, Nashville, TN, USA","institution_ids":["https://openalex.org/I4210100810"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025836672","display_name":"Shirish M. Gadgeel","orcid":"https://orcid.org/0000-0001-5240-3811","observed_orcids":["https://orcid.org/0000-0001-5240-3811"]},"institutions":[{"id":"https://openalex.org/I154057602","display_name":"Henry Ford Health","ror":"https://ror.org/02kwnkm68","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I154057602"]},{"id":"https://openalex.org/I2803043754","display_name":"Henry Ford Hospital","ror":"https://ror.org/0193sb042","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I154057602","https://openalex.org/I2803043754"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shirish Gadgeel","raw_affiliation_strings":["Department of Internal Medicine, Henry Ford Cancer Institute, Henry Ford Health System, Detroit, MI, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Internal Medicine, Henry Ford Cancer Institute, Henry Ford Health System, Detroit, MI, USA","institution_ids":["https://openalex.org/I154057602","https://openalex.org/I2803043754"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044613951","display_name":"Alexander I. Spira","orcid":"https://orcid.org/0000-0003-1303-0447","observed_orcids":["https://orcid.org/0000-0003-1303-0447"]},"institutions":[{"id":"https://openalex.org/I4210122908","display_name":"Virginia Cancer Specialists","ror":"https://ror.org/03tbabt10","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210122908"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alexander Spira","raw_affiliation_strings":["Virginia Cancer Specialists, Fairfax, VA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Virginia Cancer Specialists, Fairfax, VA, USA","institution_ids":["https://openalex.org/I4210122908"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055074037","display_name":"James Chih\u2010Hsin Yang","orcid":"https://orcid.org/0000-0002-5586-5138","observed_orcids":["https://orcid.org/0000-0002-5586-5138"]},"institutions":[{"id":"https://openalex.org/I16733864","display_name":"National Taiwan University","ror":"https://ror.org/05bqach95","country_code":"TW","type":"education","lineage":["https://openalex.org/I16733864"]},{"id":"https://openalex.org/I4210131804","display_name":"National Taiwan University Hospital","ror":"https://ror.org/03nteze27","country_code":"TW","type":"healthcare","lineage":["https://openalex.org/I4210131804"]}],"countries":["TW"],"is_corresponding":false,"raw_author_name":"James Yang","raw_affiliation_strings":["National Taiwan University and Department of Oncology, National Taiwan University Hospital, Taipei City, Taiwan, Republic of China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"National Taiwan University and Department of Oncology, National Taiwan University Hospital, Taipei City, Taiwan, Republic of China","institution_ids":["https://openalex.org/I16733864","https://openalex.org/I4210131804"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057870296","display_name":"Jennifer S. Johnson","orcid":"https://orcid.org/0000-0002-2061-4814","observed_orcids":["https://orcid.org/0000-0002-2061-4814"]},"institutions":[{"id":"https://openalex.org/I149251103","display_name":"Thomas Jefferson University","ror":"https://ror.org/00ysqcn41","country_code":"US","type":"education","lineage":["https://openalex.org/I149251103"]},{"id":"https://openalex.org/I4210106595","display_name":"Sidney Kimmel Cancer Center","ror":"https://ror.org/010h6g454","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210106595"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jennifer Johnson","raw_affiliation_strings":["Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA","institution_ids":["https://openalex.org/I149251103","https://openalex.org/I4210106595"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082417051","display_name":"Taryn R. Losch-Beridon","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Taryn Losch-Beridon","raw_affiliation_strings":["Numab Therapeutics AG, W\u00e4denswil Switzer, W\u00e4denswil, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Numab Therapeutics AG, W\u00e4denswil Switzer, W\u00e4denswil, Switzerland","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086778688","display_name":"Daniel C. Snell","orcid":"https://orcid.org/0000-0003-0107-4821","observed_orcids":["https://orcid.org/0000-0003-0107-4821"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Daniel Snell","raw_affiliation_strings":["Numab Therapeutics AG, W\u00e4denswil Switzer, W\u00e4denswil, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Numab Therapeutics AG, W\u00e4denswil Switzer, W\u00e4denswil, Switzerland","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050277620","display_name":"Stefan Warmuth","orcid":"https://orcid.org/0000-0001-6872-8805","observed_orcids":["https://orcid.org/0000-0001-6872-8805"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Stefan Warmuth","raw_affiliation_strings":["Numab Therapeutics AG, W\u00e4denswil Switzer, W\u00e4denswil, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Numab Therapeutics AG, W\u00e4denswil Switzer, W\u00e4denswil, Switzerland","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035414865","display_name":"Maureen Cleaver","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Maureen Cleaver","raw_affiliation_strings":["Numab Therapeutics AG, W\u00e4denswil Switzer, W\u00e4denswil, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Numab Therapeutics AG, W\u00e4denswil Switzer, W\u00e4denswil, Switzerland","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112153316","display_name":"Elmar vom Baur","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Elmar vom Baur","raw_affiliation_strings":["Numab Therapeutics AG, W\u00e4denswil Switzer, W\u00e4denswil, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Numab Therapeutics AG, W\u00e4denswil Switzer, W\u00e4denswil, Switzerland","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024092276","display_name":"David Urech","orcid":"https://orcid.org/0009-0003-2167-7440","observed_orcids":["https://orcid.org/0009-0003-2167-7440"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"David Urech","raw_affiliation_strings":["Numab Therapeutics AG, W\u00e4denswil Switzer, W\u00e4denswil, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Numab Therapeutics AG, W\u00e4denswil Switzer, W\u00e4denswil, Switzerland","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028533210","display_name":"Peter Lichtlen","orcid":"https://orcid.org/0009-0002-3441-0553","observed_orcids":["https://orcid.org/0009-0002-3441-0553"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Peter Lichtlen","raw_affiliation_strings":["Numab Therapeutics AG, W\u00e4denswil Switzer, W\u00e4denswil, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Numab Therapeutics AG, W\u00e4denswil Switzer, W\u00e4denswil, Switzerland","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5026095888","display_name":"David S. Hong","orcid":"https://orcid.org/0000-0001-8721-1609","observed_orcids":["https://orcid.org/0000-0001-8721-1609"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David Hong","raw_affiliation_strings":["Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":12,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":3,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":"A764","last_page":"A764"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/trispecific-antibodies","display_name":"trispecific antibodies","score":0.9269999861717224},{"id":"https://openalex.org/keywords/pd-l1-blockade","display_name":"PD-L1 blockade","score":0.9430000185966492},{"id":"https://openalex.org/keywords/anti-pd-1-therapy","display_name":"anti-PD-1 therapy","score":0.7480000257492065},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.7279999852180481},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8309999704360962},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.9430000185966492},{"id":"https://openalex.org/keywords/anti-drug-antibodies","display_name":"anti-drug antibodies","score":0.781000018119812},{"id":"https://openalex.org/keywords/tumor-infiltrating-lymphocytes","display_name":"tumor-infiltrating lymphocytes","score":0.5920000076293945},{"id":"https://openalex.org/keywords/tumor-immune-microenvironment","display_name":"tumor immune microenvironment","score":0.35100001096725464},{"id":"https://openalex.org/keywords/metastatic-solid-tumors","display_name":"metastatic solid tumors","score":0.8199999928474426},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.6019999980926514}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6666465997695923},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.6530927419662476},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6390695571899414},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.5483723878860474},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.5347845554351807},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.5319561958312988},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4796217381954193},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.46057820320129395},{"id":"https://openalex.org/C19831878","wikidata":"https://www.wikidata.org/wiki/Q659446","display_name":"Therapeutic index","level":3,"score":0.44305628538131714},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.44035646319389343},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.42405465245246887},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4149370491504669},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4083009660243988},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.33287203311920166},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.303739070892334},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.2167702615261078},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.14154064655303955}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1136/jitc-2022-sitc2022.0732","doi":"https://doi.org/10.1136/jitc-2022-sitc2022.0732","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2022-sitc2022.0732","pdf_url":"https://jitc.bmj.com/content/jitc/10/Suppl_2/A764.full.pdf","source":{"id":"https://openalex.org/S4363604233","display_name":"Regular and Young Investigator Award Abstracts","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular and Young Investigator Award Abstracts","raw_type":"proceedings-article"}],"best_oa_location":{"id":"doi:10.1136/jitc-2022-sitc2022.0732","doi":"https://doi.org/10.1136/jitc-2022-sitc2022.0732","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2022-sitc2022.0732","pdf_url":"https://jitc.bmj.com/content/jitc/10/Suppl_2/A764.full.pdf","source":{"id":"https://openalex.org/S4363604233","display_name":"Regular and Young Investigator Award Abstracts","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular and Young Investigator Award Abstracts","raw_type":"proceedings-article"},"sustainable_development_goals":[{"score":0.98580002784729,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"score":0.8600000143051147,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320308380","display_name":"Yale University","ror":"https://ror.org/03v76x132"},{"id":"https://openalex.org/F4320312423","display_name":"Yale Cancer Center","ror":"https://ror.org/03j7sze86"},{"id":"https://openalex.org/F4320322649","display_name":"Universidad de Navarra","ror":"https://ror.org/02rxc7m23"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4308384128.pdf","grobid_xml":"https://content.openalex.org/works/W4308384128.grobid-xml"},"referenced_works_count":1,"referenced_works":["https://openalex.org/W4205738423"],"related_works":["https://openalex.org/W4282960031","https://openalex.org/W3081687353","https://openalex.org/W4205738423","https://openalex.org/W4379283458","https://openalex.org/W4410805370","https://openalex.org/W7162575248","https://openalex.org/W4399662746","https://openalex.org/W4399324942","https://openalex.org/W4399325302","https://openalex.org/W4399738000"],"abstract_inverted_index":{"Background":[0],"NM21-1480":[1,26,87,178,333,342],"is":[2,522],"a":[3,47,150,171,205,309,348,363,506],"tri-specific":[4],"Fc-lacking":[5],"antibody":[6,117],"that":[7,557],"agonizes":[8],"4-1BB":[9,20,36,301,511],"and":[10,33,105,115,123,231,247,305,325,400,433,464,472,513,538,574],"blocks":[11],"PD-L1/PD-1":[12],"signaling,":[13],"designed":[14],"to":[15,22,39,237,374,381],"restrict":[16],"activation":[17],"of":[18,56,62,153,158,174,192,211,318,332,393,422,431,456,470,505,527,562],"the":[19,23,54,57,63,190,261,316,319,328,390,398,528,543,560,580],"pathway":[21],"tumor":[24],"microenvironment.1":[25],"contains":[27],"an":[28,34,286],"ultra-potent":[29],"PD-L1":[30,296,514],"blocking":[31],"moiety":[32,38],"affinity-balanced":[35],"binding":[37],"assure":[40],"maximal":[41],"activity":[42,125,294,345,355],"on":[43,295,315],"both":[44],"pathways":[45],"over":[46],"broad":[48,310],"dose":[49,191,198,263,311,331,358],"range.":[50],"Here":[51],"we":[52],"report":[53],"results":[55],"Phase":[58,66],"1":[59,202],"dose-escalation":[60],"part":[61],"ongoing":[64],"First-in-Human":[65],"1/2a":[67],"clinical":[68,326,339,354],"trial":[69,485,496,521],"with":[70,74,135,347,367,555],"NM21-1480.":[71],"Methods":[72],"Patients":[73,146],"metastatic":[75],"or":[76,96,194,377],"unresectable":[77],"solid":[78,138,369],"tumors":[79,139],"not":[80,200],"eligible":[81],"for":[82,337,405,480],"standard":[83],"therapy":[84],"received":[85,149,170],"flat-dose":[86],"(0.15\u2013800mg)":[88],"intravenously":[89],"every":[90],"2":[91],"weeks":[92],"until":[93],"disease":[94,265,271],"progression":[95],"unacceptable":[97],"toxicity.":[98],"Primary":[99],"endpoints":[100,110],"were":[101,127,140,219],"dose-limiting":[102],"toxicities":[103],"(DLTs)":[104],"adverse":[106,253],"events":[107],"(AEs).":[108],"Secondary":[109],"included":[111],"pharmacokinetic":[112],"(PK)":[113],"parameters":[114],"anti-drug":[116],"(ADA)":[118],"assessments.":[119],"Pharmacodynamic":[120],"(PD)":[121],"biomarkers":[122],"antitumor":[124],"(RECIST1.1)":[126],"assessed":[128],"as":[129,298,300],"exploratory":[130],"endpoints.":[131],"Results":[132],"26":[133],"patients":[134,169,281,399],"various":[136],"primary":[137],"enrolled":[141],"(median":[142],"age:":[143],"63":[144],"years).":[145],"had":[147,160],"previously":[148],"median":[151,172],"(range)":[152,173],"3.5":[154],"(1\u201310)":[155],"treatments;":[156],"62%":[157],"whom":[159],"prior":[161,375],"anti-PD-(L)1":[162],"immunotherapy.":[163],"As":[164],"per":[165],"14":[166],"July":[167],"2022":[168],"4":[175],"(1-19)":[176],"biweekly":[177],"infusions.":[179],"Full":[180],"peripheral":[181],"receptor":[182],"occupancy":[183],"at":[184,189,224,268,272,275,290,308,458],"trough":[185],"level":[186],"was":[187,199,303,360,486,577],"observed":[188,304,361],"24mg":[193],"above.":[195],"Maximum":[196],"tolerated":[197],"reached;":[201],"patient":[203,240,284],"experienced":[204,242],"DLT.":[206],"The":[207,411],"most":[208],"common":[209],"(\u226510%":[210],"patients)":[212],"treatment-related":[213,243,252],"AEs":[214],"(all":[215],"grades;":[216],"Grades":[217],"3\u20134)":[218],"infusion-related":[220],"reactions":[221],"(27%":[222],"(11%":[223],"800mg":[225,329],"dose);":[226],"0%),":[227],"fatigue":[228],"(12%;":[229,234],"0%)":[230],"transaminase":[232,245],"elevations":[233,246],"4%)":[235],"according":[236],"CTCAEv5.0.":[238],"One":[239,283],"each":[241],"Grade-3":[244],"adrenal":[248],"insufficiency,":[249],"respectively;":[250],"no":[251],"event":[254],"higher":[255],"than":[256],"Grade":[257],"3":[258],"occurred.":[259],"In":[260],"24mg-800mg":[262],"range,":[264],"control,":[266],"i.e.,":[267],"least":[269],"stable":[270,307],"first":[273],"assessment":[274],"8":[276],"weeks,":[277],"occurred":[278],"in":[279,362,389,408,553,559],"12/21":[280],"(57%).":[282],"demonstrated":[285,343],"unconfirmed":[287],"partial":[288],"response":[289],"Week":[291],"16.":[292],"PD":[293],"blockade":[297],"well":[299],"signaling":[302],"remained":[306],"range":[312],"(24-800mg).":[313],"Based":[314],"totality":[317],"data":[320],"derived":[321],"from":[322],"safety/immunogenicity,":[323],"PK/PD":[324],"activity,":[327],"flat":[330],"has":[334],"been":[335],"selected":[336],"further":[338],"evaluation.":[340],"Conclusions":[341],"biological":[344],"associated":[346],"manageable":[349],"safety":[350],"profile.":[351],"Encouraging":[352],"early":[353],"across":[356],"different":[357],"levels":[359],"heavily":[364],"pretreated":[365],"population":[366],"advanced":[368],"tumors,":[370],"including":[371,568],"those":[372],"resistant":[373],"immunotherapy":[376,509],"typically":[378],"less":[379],"sensitive":[380],"ICIs.":[382],"Enrollment":[383],"into":[384],"expansion":[385],"cohorts":[386],"will":[387],"start":[388],"second":[391],"half":[392],"2022.":[394],"Acknowledgements":[395],"We":[396],"thank":[397,413],"all":[401],"involved":[402],"site":[403],"personnel":[404],"their":[406,481],"participation":[407],"this":[409],"trial.":[410],"authors":[412],"Dr.":[414,427,441,451,465],"Mario":[415],"Sznol":[416],"(Yale":[417],"Cancer":[418,447],"Center,":[419,448],"Yale":[420],"School":[421,455],"Medicine,":[423],"New":[424,461],"Haven,":[425],"USA),":[426,450],"Ignacio":[428],"Melero":[429],"(Department":[430],"Immunology":[432],"Immunotherapy,":[434],"Clinica":[435],"Universidad":[436,475],"de":[437,476],"Navarra,":[438,477],"Pamplona,":[439,478],"Spain),":[440],"Robert":[442],"L.":[443],"Ferris":[444],"(UPMC":[445],"Hillman":[446],"Pittsburgh,":[449],"Matthew":[452],"Galsky":[453],"(Icahn":[454],"Medicine":[457],"Mount":[459],"Sinai,":[460],"York,":[462],"USA)":[463],"Miguel":[466],"F.":[467],"Sanmamed":[468],"(Departments":[469],"Oncology":[471],"Immunology,":[473],"Cl\u00ednica":[474],"Spain)":[479],"valuable":[482],"contributions.":[483],"This":[484,520],"funded":[487],"by":[488,542,579],"Numab":[489],"Therapeutics":[490],"AG.":[491],"Trial":[492],"Registration":[493],"ClinicalTrials.":[494],"gov;":[495],"number:":[497],"NCT04442126":[498],"Reference":[499],"Warmuth":[500],"S":[501],"et":[502],"al.":[503],"Engineering":[504],"trispecific":[507],"tumor-targeted":[508],"incorporating":[510],"co-stimulation":[512],"blockade.":[515],"Oncoimmunology.":[516],"2021;10(1):e2004661":[517],"Ethics":[518,545],"Approval":[519],"undertaken":[523],"following":[524],"full":[525],"approval":[526],"final":[529],"protocol,":[530],"amendments,":[531],"informed":[532,551],"consent":[533],"form,":[534],"applicable":[535,571],"recruiting":[536],"materials,":[537],"subject":[539],"compensation":[540],"programs":[541],"Independent":[544],"Committee/Institutional":[546],"Review":[547],"Board.":[548],"Consent":[549],"Written":[550],"consent,":[552],"accordance":[554],"principles":[556],"originated":[558],"Declaration":[561],"Helsinki":[563],"2013,":[564],"current":[565],"ICH":[566],"guidelines":[567],"ICH-GCP":[569],"E6(R2),":[570],"regulatory":[572],"requirements,":[573],"sponsor":[575],"policy,":[576],"provided":[578],"patients.":[581]},"counts_by_year":[{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":1}],"updated_date":"2026-10-01T08:54:57.152042","created_date":"2022-11-11T00:00:00"}